Genmab Stock - analyst consensus and growth expectations

Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/22/2026, 02:21 UTC. Details in the imprint.

Genmab (DK0010272202) remains closely watched by biotech investors as a mid-to-large-cap antibody specialist with a solid partner network. Analyst consensus and valuation metrics provide a structured view on how the market currently prices its growth prospects.

What recent estimates show

Genmab is followed by a compact but active analyst community on both sides of the Atlantic. According to a recent consensus snapshot compiled ahead of the company’s first-quarter 2026 report, the market looked for about $905.8 million in quarterly revenue and earnings per share around $0.15.

That preview highlighted that Genmab stock traded at roughly 1.96x trailing 12-month sales at the time, a valuation that sits in the mid-range for profitable biotech peers with marketed oncology products. The same update pointed to a drawdown of about 31% from the 52-week high near $35.43, underscoring a more cautious risk appetite.

How analysts rate Genmab

The same consensus overview described a supportive stance from covering analysts, with all 12 tracked ratings in the Buy category and no Holds or Sells registered at that time. That breadth of positive recommendations is robust for a single-product-heavy biotech and suggests confidence in the pipeline and partnered assets.

While targets and recommendations shift as data and earnings arrive, this setup frames a constructive starting point. A full analyst distribution, including individual price targets and rating histories, is available via the company’s US-listed GMAB quote pages on major market-data platforms.

The product engine behind the numbers

Genmab’s investment case is anchored in antibody therapeutics, led by the cancer treatment Daratumumab, marketed as Darzalex by Janssen under a long-standing collaboration. The company also receives revenue from other partnered antibodies and its proprietary technology platforms, which generate milestone and royalty streams.

Where the stock trades today

The shares of Genmab (DK0010272202) trade on Nasdaq in New York under the ticker GMAB; the latest verifiable quote on widely used data services shows the stock changing hands in US dollars, with real-time pricing available during US market hours.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.